Alemtuzumab in refractory Sézary syndrome. - Test2 - elhamkhani - TriplyDB

Alemtuzumab in refractory Sézary syndrome.

Alemtuzumab in refractory Sézary syndrome.

http://www.wikidata.org/entity/Q42377651

about

Alemtuzumab in refractory Sézary syndrome.

http://www.wikidata.org/entity/Q42377651

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Alemtuzumab in refractory Sézary syndrome.

@en

Alemtuzumab in refractory Sézary syndrome.

@nl

type

label

Alemtuzumab in refractory Sézary syndrome.

@en

Alemtuzumab in refractory Sézary syndrome.

@nl

prefLabel

Alemtuzumab in refractory Sézary syndrome.

@en

Alemtuzumab in refractory Sézary syndrome.

@nl

P1433

Q42377651-4B93C0B6-76B4-43B1-A2B8-2AB0DF40108F

P1476

Q42377651-90375667-DE75-4583-82BF-740972F9D203

P2093

Q42377651-4312197E-0BC1-42E1-9488-61A64AD9076E

Q42377651-663C8015-93D8-4C2D-89F2-E819F449BA89

Q42377651-762B5A55-4E7F-4A27-BE21-C4DCB242F3DB

Q42377651-9357D1E4-8F56-4C76-9E54-FB80A0836B1C

Q42377651-C3EB2DF3-A2C3-49F6-B272-FDC70E5B86FE

P2860

Q42377651-090CB4AC-9937-4A3A-93F1-898FE5030E58

Q42377651-123A18BD-6524-4D4B-9330-484DE5A7EA07

Q42377651-36991041-9342-4034-B11C-280F1E98DEAA

Q42377651-4F9B8D2F-EB17-484C-A74E-B01B514D94D2

Q42377651-753D561E-AC05-4F4F-A67E-76668C0D3817

Q42377651-B61AD34E-8295-4E0E-AFB9-499DE170BAFE

Q42377651-DBA3525F-2D39-408F-8147-6AF255D97107

P304

Q42377651-7366512E-7CC9-436F-A00F-CE8679917B13

P31

Q42377651-06B75571-8667-42D6-BF38-0D4AD52E626E

Q42377651-3dd3428c-34ef-4e62-ab94-fb975ab163ce

P356

Q42377651-5B66D64D-D571-4A99-BC41-6B0385F9139C

P433

Q42377651-941ADFA1-DAF9-4F92-891F-5D30DF6FF5F9

P478

Q42377651-AC498724-5F6F-4D31-A114-E0EC2CC8C1BE

P50

Q42377651-3F92E73C-23CB-446C-BD40-A0755DD7C4F2

P577

Q42377651-1A850266-9BD9-45D1-8F71-55F5A707187E

P698

Q42377651-FF8CE467-337E-486B-A57A-47A286E1ABD6

P932

Q42377651-2D774A7B-A1AF-485B-A95A-9765421C3B31

P356

ABD1806-4841.20164322

P1433

Anais Brasileiros de Dermatologia

P1476

Alemtuzumab in refractory Sézary syndrome

@en

P2093

Alberto González-Menchen

http://www.w3.org/2001/XMLSchema#string

Antonio Vélez García-Nieto

http://www.w3.org/2001/XMLSchema#string

Carmen María Alcántara Reifs

http://www.w3.org/2001/XMLSchema#string

Gloria María Garnacho-Saucedo

http://www.w3.org/2001/XMLSchema#string

Sofía De la Corte-Sánchez

http://www.w3.org/2001/XMLSchema#string

P2860

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.

New and established treatment options for mycosis fungoides and Sézary syndrome - an update.

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.

Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.

Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.

Alemtuzumab in Sézary syndrome: efficient but not innocent.

P304

642-644

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1590/ABD1806-4841.20164322

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

91

http://www.w3.org/2001/XMLSchema#string

P50

R Salido-Vallejo

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27828640

http://www.w3.org/2001/XMLSchema#string

P932

5087225

http://www.w3.org/2001/XMLSchema#string